Zoë Vander Elst
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zoë Vander Elst has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Karel Allegaert
Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium, Leuven, Belgium; Department of Development and Regeneration, Catholic University of Leuven, Leuven, Belgium; Department of Hospital Pharmacy, Erasmus MC, Rotterdam, The Netherlands, Belgium
5 shared publications - Anne Smits
Department of Development and Regeneration, KU Leuven, Leuven, Belgium
3 shared publications - Matthias Gijsen
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
3 shared publications Anne Smits
Neonatal Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium
2 shared publications- Erwin Dreesen
Department of Pharmaceutical and Pharmacological Sciences KU Leuven Leuven Belgium
2 shared publications - Isabel Spriet
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
Neonatal late-onset sepsis recovery score: a clinical cure score for neonates with late-onset sepsis (Neo-ROSA score)
Objective Late-onset sepsis (LOS) remains a major cause of neonatal mortality, yet accurate endpoints to monitor recovery are lacking. Though clinical cure is commonly used as a core outcome in trials, no consensus definition exists. This study aimed to develop a clinical cure score to monitor recovery in neonatal LOS. Design A multidisciplinary expert panel reached consensus on items using a modified Delphi approach (development phase). Content validity was quantified using the Content Validity Index (CVI). Face validity was assessed through end-user surveys evaluating comprehensibility and user-friendliness. Inter-rater/intrarater reliability was examined by having end-users score six video-fragments twice (evaluation phase). Intraclass correlation coefficients (ICCs) were calculated. A prospective pilot study compared scores between sepsis and control patients to propose a clinical cure cut-off (validation phase). Results Nine experts needed seven surveys and nine meetings to reach predefined CVI targets. 87 end-users completed the face validity survey, rating comprehensibility and user-friendliness 4.4/5. The final score comprised nine clinical items, with maximum scores of 24 (ventilated) and 27 (non-ventilated), following a ‘back-to-baseline’ concept. Inter-rater ICCs were 0.68 (absolute agreement) and 0.75 (consistency) among 52 raters. Intrarater ICC was 0.83 (31 raters). 15 sepsis and 17 control patients were included in the prospective study. Median scores of sepsis patients improved over time until reaching scores of controls. Proposed clinical cure cut-offs were >20 for ventilated and >23 for non-ventilated neonates. Conclusions The Neonatal Recovery Of Sepsis Assessment score provides a promising, user-friendly tool that standardises clinical cure assessment in research and may support future clinical follow-up of LOS neonates.
- 23 October 2026
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
Open AccessNeonatal late-onset sepsis recovery score: a clinical cure score for neonates with late-onset sepsis (Neo-ROSA score)
Objective Late-onset sepsis (LOS) remains a major cause of neonatal mortality, yet accurate endpoints to monitor recovery are lacking. Though clinical cure is commonly used as a core outcome in trials, no consensus definition exists. This study aimed to develop a clinical cure score to monitor recovery in neonatal LOS. Design A multidisciplinary expert panel reached consensus on items using a modified Delphi approach (development phase). Content validity was quantified using the Content Validity Index (CVI). Face validity was assessed through end-user surveys evaluating comprehensibility and user-friendliness. Inter-rater/intrarater reliability was examined by having end-users score six video-fragments twice (evaluation phase). Intraclass correlation coefficients (ICCs) were calculated. A prospective pilot study compared scores between sepsis and control patients to propose a clinical cure cut-off (validation phase). Results Nine experts needed seven surveys and nine meetings to reach predefined CVI targets. 87 end-users completed the face validity survey, rating comprehensibility and user-friendliness 4.4/5. The final score comprised nine clinical items, with maximum scores of 24 (ventilated) and 27 (non-ventilated), following a ‘back-to-baseline’ concept. Inter-rater ICCs were 0.68 (absolute agreement) and 0.75 (consistency) among 52 raters. Intrarater ICC was 0.83 (31 raters). 15 sepsis and 17 control patients were included in the prospective study. Median scores of sepsis patients improved over time until reaching scores of controls. Proposed clinical cure cut-offs were >20 for ventilated and >23 for non-ventilated neonates. Conclusions The Neonatal Recovery Of Sepsis Assessment score provides a promising, user-friendly tool that standardises clinical cure assessment in research and may support future clinical follow-up of LOS neonates.
- Open Access
- 24 March 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (7) , 2028-2048
Systematic review and scoring‐based selection of pharmacokinetic models for precision dosing of vancomycin in neonates and children
Vancomycin is frequently used to treat gram‐positive infections in neonates and children. The optimal marker for efficacy and toxicity is the 24‐h area under the concentration‐time curve/minimal inhibitory concentration, which can be estimated using population pharmacokinetic (popPK) models. These models can be integrated into model‐informed precision dosing (MIPD) tools to personalize therapy. This study aimed to systematically review neonatal and paediatric vancomycin popPK models and develop a model selection tool for MIPD. A systematic literature search (December 2025; PubMed, EMBASE, WoS, Scopus, IPA) was conducted following PRISMA guidelines using the concepts ‘neonates/children’, ‘vancomycin’ and ‘popPK model’. Inclusion criteria were age 0–18 years, intravenous vancomycin, and popPK model development. Descriptive statistics summarized tested vs . retained covariates. Based on literature and multidisciplinary expert input, model selection criteria were proposed and applied to the identified models. Across 7915 articles, 112 popPK models were identified (1994–2025; 35 neonatal, 6 infantile, 39 paediatric, 2 adolescent, 30 mixed‐age). Models were built on data from median (range) 114 (6–7167) patients, representing 337 (26–13 372) PK samples. There were 81 one‐ and 30 two‐compartment models. Of 180 covariates tested across models, 47 (26.1%) were retained. Body weight was most frequently tested and retained (101/106, 95.3%). Model selection criteria included matching population, external and internal model evaluation (calibration, discrimination, uncertainty), cohort size, PK sampling schedule. The Chen (2023) model scored highest for both the neonatal and paediatric populations. This review and model selection tool can guide and standardize model selection for MIPD.
- 24 March 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (7) , 2028-2048
Open AccessSystematic review and scoring‐based selection of pharmacokinetic models for precision dosing of vancomycin in neonates and children
Vancomycin is frequently used to treat gram‐positive infections in neonates and children. The optimal marker for efficacy and toxicity is the 24‐h area under the concentration‐time curve/minimal inhibitory concentration, which can be estimated using population pharmacokinetic (popPK) models. These models can be integrated into model‐informed precision dosing (MIPD) tools to personalize therapy. This study aimed to systematically review neonatal and paediatric vancomycin popPK models and develop a model selection tool for MIPD. A systematic literature search (December 2025; PubMed, EMBASE, WoS, Scopus, IPA) was conducted following PRISMA guidelines using the concepts ‘neonates/children’, ‘vancomycin’ and ‘popPK model’. Inclusion criteria were age 0–18 years, intravenous vancomycin, and popPK model development. Descriptive statistics summarized tested vs . retained covariates. Based on literature and multidisciplinary expert input, model selection criteria were proposed and applied to the identified models. Across 7915 articles, 112 popPK models were identified (1994–2025; 35 neonatal, 6 infantile, 39 paediatric, 2 adolescent, 30 mixed‐age). Models were built on data from median (range) 114 (6–7167) patients, representing 337 (26–13 372) PK samples. There were 81 one‐ and 30 two‐compartment models. Of 180 covariates tested across models, 47 (26.1%) were retained. Body weight was most frequently tested and retained (101/106, 95.3%). Model selection criteria included matching population, external and internal model evaluation (calibration, discrimination, uncertainty), cohort size, PK sampling schedule. The Chen (2023) model scored highest for both the neonatal and paediatric populations. This review and model selection tool can guide and standardize model selection for MIPD.
- Open Access
- 11 February 2025
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (7) , 923-932
Mathematical Albumin Function for Neonates Undergoing Therapeutic Hypothermia in Comparison with Control Neonates
Hypoxic‐ischemic encephalopathy (HIE) resulting from perinatal asphyxia presents a substantial risk of mortality and long‐term sequelae in neonates. Therapeutic hypothermia (TH) improves both short‐ and long‐term outcomes in near‐term/term neonates with moderate to severe HIE. While neonates with perinatal asphyxia and TH often require polypharmacy, the impact of both covariates on pharmacokinetics and pharmacodynamics is only partially described and quantified. In this pooled, multicenter retrospective study, longitudinal trends of human serum albumin (HSA, the major drug binding protein) and total protein (TP) concentrations in near‐term/term neonates were described using linear mixed models and compared between cohorts (TH vs control neonates, and moderate vs severe HIE TH cases). A mathematical function for HSA concentrations in neonates with HIE undergoing TH was derived (AlbuCool function). The pooled dataset to estimate these functions contained 330 TH neonates and 425 controls with 1725 and 1415 HSA observations, respectively. The median (interquartile range) HSA concentration was 27.0 (23.0‐31.0) g/L for the TH cohort, and 32.1 (28.4‐35.7) g/L for the control cohort. Estimated mean HSA concentrations were significantly lower (P < .001) in TH compared to control cases, as well as in severe compared to moderate HIE cases (P < .001) over the first 7 postnatal days. The HSA function for neonates with HIE undergoing TH was: HSA (g/L) = 32.28 − 2.94 * PNA + 0.33 * PNA2 (PNA is postnatal age). The integration of this function in pharmacokinetic models holds the promise to improve the predictive performance of these models, and consequently, the pharmacotherapy of HSA‐bound drugs in this vulnerable population.
- 11 February 2025
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (7) , 923-932
Open AccessMathematical Albumin Function for Neonates Undergoing Therapeutic Hypothermia in Comparison with Control Neonates
Hypoxic‐ischemic encephalopathy (HIE) resulting from perinatal asphyxia presents a substantial risk of mortality and long‐term sequelae in neonates. Therapeutic hypothermia (TH) improves both short‐ and long‐term outcomes in near‐term/term neonates with moderate to severe HIE. While neonates with perinatal asphyxia and TH often require polypharmacy, the impact of both covariates on pharmacokinetics and pharmacodynamics is only partially described and quantified. In this pooled, multicenter retrospective study, longitudinal trends of human serum albumin (HSA, the major drug binding protein) and total protein (TP) concentrations in near‐term/term neonates were described using linear mixed models and compared between cohorts (TH vs control neonates, and moderate vs severe HIE TH cases). A mathematical function for HSA concentrations in neonates with HIE undergoing TH was derived (AlbuCool function). The pooled dataset to estimate these functions contained 330 TH neonates and 425 controls with 1725 and 1415 HSA observations, respectively. The median (interquartile range) HSA concentration was 27.0 (23.0‐31.0) g/L for the TH cohort, and 32.1 (28.4‐35.7) g/L for the control cohort. Estimated mean HSA concentrations were significantly lower (P < .001) in TH compared to control cases, as well as in severe compared to moderate HIE cases (P < .001) over the first 7 postnatal days. The HSA function for neonates with HIE undergoing TH was: HSA (g/L) = 32.28 − 2.94 * PNA + 0.33 * PNA2 (PNA is postnatal age). The integration of this function in pharmacokinetic models holds the promise to improve the predictive performance of these models, and consequently, the pharmacotherapy of HSA‐bound drugs in this vulnerable population.
- Open Access
- 11 October 2024
- Published by Springer Nature in Pediatric Research
- Vol. 99 (2) , 604-611
Human serum albumin: prediction model and reference values for preterm and term neonates
Background: Human serum albumin (HSA) concentrations may alter HSA-bound drug distribution. This study aims to describe longitudinal real-world HSA trends, and to develop a prediction model for HSA concentrations using a large neonatal cohort. Methods: Patients admitted to the neonatal intensive care unit of the University Hospitals Leuven (postnatal age (PNA) ≤28days) were retrospectively included. Using linear mixed models, covariate effects on HSA were explored. A multivariable prediction model was developed (backward model selection procedure, 1% significance level). Results: In total, 848 neonates were included [median(interquartile range) gestational age (GA) 35(32–38)weeks, birth weight (BW) 2400(1640–3130)grams]. Median HSA concentration was 32.3(28.7–35.6)g/L. Longitudinal analyses demonstrated increasing HSA concentrations with PNA and GA for most GA groups. Univariable analyses revealed significant associations of HSA with PNA, GA, BW, current weight, total and direct bilirubin, total plasma proteins, respiratory support, mechanical ventilation, sepsis, ibuprofen use, and C-reactive protein ( p -values < 0.05). A high-performance (R 2 = 76.3%) multivariable HSA prediction model was developed, and PNA- and GA-dependent HSA centiles were provided. Conclusion: Population-specific HSA centiles and an accurate neonatal HSA prediction model were developed, incorporating both maturational and non-maturational covariates. These results can enhance future clinical care and pharmacokinetic analyses to improve pharmacotherapy of HSA-bound drugs in neonates, respectively. Impact: To improve future pharmacokinetic modeling initiatives, a high-performance human serum albumin (HSA) prediction model was developed for (pre)term neonates, using a large, single-center cohort of real-world data. This prediction model integrates both maturational and non-maturational covariates, resulting in accurate HSA predictions in neonates. Additionally, HSA centiles based on postnatal and gestational age were developed, which can be easily applied in clinical practice when interpreting HSA concentrations of neonates. In general, unbound drug fractions are higher in neonates compared to older populations. To improve pharmacotherapy of HSA-bound drugs in neonates, the obtained results can be integrated in future pharmacokinetic-pharmacodynamic analyses.
- 11 October 2024
- Published by Springer Nature in Pediatric Research
- Vol. 99 (2) , 604-611
Open AccessHuman serum albumin: prediction model and reference values for preterm and term neonates
Background: Human serum albumin (HSA) concentrations may alter HSA-bound drug distribution. This study aims to describe longitudinal real-world HSA trends, and to develop a prediction model for HSA concentrations using a large neonatal cohort. Methods: Patients admitted to the neonatal intensive care unit of the University Hospitals Leuven (postnatal age (PNA) ≤28days) were retrospectively included. Using linear mixed models, covariate effects on HSA were explored. A multivariable prediction model was developed (backward model selection procedure, 1% significance level). Results: In total, 848 neonates were included [median(interquartile range) gestational age (GA) 35(32–38)weeks, birth weight (BW) 2400(1640–3130)grams]. Median HSA concentration was 32.3(28.7–35.6)g/L. Longitudinal analyses demonstrated increasing HSA concentrations with PNA and GA for most GA groups. Univariable analyses revealed significant associations of HSA with PNA, GA, BW, current weight, total and direct bilirubin, total plasma proteins, respiratory support, mechanical ventilation, sepsis, ibuprofen use, and C-reactive protein ( p -values < 0.05). A high-performance (R 2 = 76.3%) multivariable HSA prediction model was developed, and PNA- and GA-dependent HSA centiles were provided. Conclusion: Population-specific HSA centiles and an accurate neonatal HSA prediction model were developed, incorporating both maturational and non-maturational covariates. These results can enhance future clinical care and pharmacokinetic analyses to improve pharmacotherapy of HSA-bound drugs in neonates, respectively. Impact: To improve future pharmacokinetic modeling initiatives, a high-performance human serum albumin (HSA) prediction model was developed for (pre)term neonates, using a large, single-center cohort of real-world data. This prediction model integrates both maturational and non-maturational covariates, resulting in accurate HSA predictions in neonates. Additionally, HSA centiles based on postnatal and gestational age were developed, which can be easily applied in clinical practice when interpreting HSA concentrations of neonates. In general, unbound drug fractions are higher in neonates compared to older populations. To improve pharmacotherapy of HSA-bound drugs in neonates, the obtained results can be integrated in future pharmacokinetic-pharmacodynamic analyses.
- Open Access
- 6 March 2024
- Published by Springer Nature in Pediatric Research
- Vol. 96 (1) , 81-88
Publication Recommendations to Report Laboratory Data of Neonates – a Modified Delphi Approach
Background: Clinical and analytical information on laboratory data of neonates in scientific publications is sparse and incomplete. Furthermore, interpreting neonatal laboratory data can be complex due to their time-dependent and developmental physiology, and paucity of well-established age-appropriate reference ranges for neonates. This study aims to develop publication recommendations to report laboratory data of neonates to enhance the quality of these data in research and clinical care. Methods: A modified Delphi approach was used to develop recommendations in cooperation with the International Neonatal Consortium. A Core Group, including different stakeholders, was responsible for developing the recommendations, in collaboration with a Reflection Group, responsible for providing additional input. Results: The recommendations were classified into three categories: ‘Clinical Characteristics’, ‘Bio-analytical Information’ and ‘Data-analytical Information’. These were each divided into ‘Core Data’ (always to be reported) and ‘Supplemental Considerations’ (to be reported when considered relevant to the study). Conclusion: Our recommendations provide guidance on standardization of neonatal laboratory data in publications. This will enhance the comparison, replication, and application of study results in research initiatives and clinical practice. Furthermore, these recommendations also serve as foundational work to develop reference ranges for neonatal laboratory values by standardizing the quality of information needed for such efforts. Impact: Standardized reporting of neonatal laboratory data in scientific publications will enhance the comparison, replication, and application of study results in research initiatives and clinical practice, as well as improve reporting to regulatory agencies. To integrate multistakeholder perspectives, a modified Delphi approach was used to develop publication recommendations which strengthens the applicability of the recommendations. Implementation of standardization will likely improve the overall quality of neonatal clinical research and neonatal healthcare. In addition, these recommendations are foundational to develop reference ranges for neonatal laboratory values by standardizing the quality of information needed for such efforts.
- 6 March 2024
- Published by Springer Nature in Pediatric Research
- Vol. 96 (1) , 81-88
Open AccessPublication Recommendations to Report Laboratory Data of Neonates – a Modified Delphi Approach
Background: Clinical and analytical information on laboratory data of neonates in scientific publications is sparse and incomplete. Furthermore, interpreting neonatal laboratory data can be complex due to their time-dependent and developmental physiology, and paucity of well-established age-appropriate reference ranges for neonates. This study aims to develop publication recommendations to report laboratory data of neonates to enhance the quality of these data in research and clinical care. Methods: A modified Delphi approach was used to develop recommendations in cooperation with the International Neonatal Consortium. A Core Group, including different stakeholders, was responsible for developing the recommendations, in collaboration with a Reflection Group, responsible for providing additional input. Results: The recommendations were classified into three categories: ‘Clinical Characteristics’, ‘Bio-analytical Information’ and ‘Data-analytical Information’. These were each divided into ‘Core Data’ (always to be reported) and ‘Supplemental Considerations’ (to be reported when considered relevant to the study). Conclusion: Our recommendations provide guidance on standardization of neonatal laboratory data in publications. This will enhance the comparison, replication, and application of study results in research initiatives and clinical practice. Furthermore, these recommendations also serve as foundational work to develop reference ranges for neonatal laboratory values by standardizing the quality of information needed for such efforts. Impact: Standardized reporting of neonatal laboratory data in scientific publications will enhance the comparison, replication, and application of study results in research initiatives and clinical practice, as well as improve reporting to regulatory agencies. To integrate multistakeholder perspectives, a modified Delphi approach was used to develop publication recommendations which strengthens the applicability of the recommendations. Implementation of standardization will likely improve the overall quality of neonatal clinical research and neonatal healthcare. In addition, these recommendations are foundational to develop reference ranges for neonatal laboratory values by standardizing the quality of information needed for such efforts.